SUBCUTANEOUS LIQUID L-DOPA FOR PARKINSON'S DISEASE

NeuroDerm have announced that the first patients with severe Parkinson’s Disease have been enrolled and dosed in a Phase IIa trial of ND0612H. ND0612H is a high-dose form of liquid

L-dopa and carbidopa (which is the same as Sinemet) but which is delivered continuously through subcutaneous administration (via the skin) by a belt-pump.

 Unlike the most comparable methods of administering L-dopa, no surgery is needed.

ND0612H is intended to replace current treatments for

people with severe Parkinson’s Disease that require highly

invasive surgery that is associated with serious side effects.

ND0612L is the low dose drug form intended for moderate Parkinson’s Disease. ND0612L has just completed patient enrollment and treatment in a Phase II double-blind,

randomised, placebo-controlled study. ND0612L was shown in previous phase I and phase IIa studies to be safe and tolerable, reaching steady state, clinically meaningful L-dopa blood concentrations.

ND0612L and ND0612H are the first liquid formulations of L-dopa and carbidopa to be administered subcutaneously (via the skin) to conveniently achieve steady state L-dopa plasma levels. L-dopa and carbidopa are otherwise nearly always administered orally, which can cause motor fluctuations and non-motor complications  n Parkinson’s Disease.

For More information http://neuroderm.com